Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 27Unknown 4Terminated 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 13Neoplasms, Plasma Cell 3Recurrence 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 2Waldenstrom Macroglobulinemia 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Polyneuropathies 1Paraproteinemias 1Mouth Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Endocrine System Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Melphalan 16Cyclophosphamide 14Dexamethasone 13fludarabine phosphate 12Filgrastim 11Antilymphocyte Serum 11fludarabine 8Radiotherapy 8Mycophenolic Acid 8Cyclosporine 8Busulfan 8Whole-Body Irradiation 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Methylprednisolone 6Lenalidomide 6Bortezomib 6pomalidomide 5Rituximab 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Flow Cytometry 4Etoposide 4Arsenic Trioxide 4liposomal doxorubicin 3Thalidomide 3Surveys and Questionnaires 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Plasma Cell × Thalidomide × Clear all
NCT01927718 2019-04-29

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 5 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00538824 2018-06-06

DexTR

Weill Medical College of Cornell University

Phase 2 Terminated
5 enrolled 8 charts
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00227682 2012-05-28

Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

OHSU Knight Cancer Institute

Phase 2 Terminated
2 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡